CAMK2B and cancer: A recent clinical trial revealed that the CAMK2 inhibitor appears to be well accepted and safe among patients (62), suggesting that it should pave the way for future development of CAMK2 inhibitors in other conditions, such as the treatment of MDR cancer patients.